Results 41 to 50 of about 2,887 (179)

Radioiodination of olmesartan medoxomil and biological evaluation of the product as a tracer for cardiac imaging

, 2017
The present study is oriented to synthesis of radioiodinated olmesartan medoxomil (OM) for potential cardiac imaging. Olmesartan medoxomil has been labeled with [125/131I] using chloramine-T (Ch-T) as an oxidizing agent. The key effective factors such as
Safaa B. Challan, M. H. Sanad, Ebtisam. A. Marzook   +2 more
core   +1 more source

Linking FHIR‐Based Medication Data to a Computable Algorithm for Heart Medication Optimization: A Critical Component of Any Medication Learning Health System

Learning Health Systems, Volume 10, Issue 1, January 2026.
ABSTRACT Introduction Despite strong evidence supporting guideline‐directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), a significant gap persists in the consistent application of these therapies. This shortfall has prompted organizations like the American College of Cardiology to recommend leveraging electronic ...
Joey LeGrand, Mohamed S. Ali, Allen Flynn, Juan Arzac, Corey Lester, Michael P. Dorsch   +5 more
wiley   +1 more source

ELASTIC VESICLES FOR ENHANCING THE TRANSDERMAL DELIVERY OF OLMESARTAN MEDOXOMIL [PDF]

Bulletin of Pharmaceutical Sciences. Assiut University
Hypertension seems to be a disorder that needs consideration for developing a transdermal drug delivery system (TDDS) because it requires long and continuing therapy. Olmesartan Medoxomil is an antihypertensive medication which has substantial first pass
reem Al-Uobody, Thair L. Jabbar, amira amin   +2 more
doaj   +1 more source

Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension - The OLMEBEST study

, 2006
peer reviewedBackground and objective: Achieving target BP is important to control the increased cardiovascular risk associated with uncontrolled hypertension.
Stefenelli, T., Krzesinski, Jean-Marie, Boccanelli, Allesandro, Boccanelli, A., Rodicio, José, Woittiez, A., Rodicio, J., Bohm, M., Heagerty, A., Ewald, S., Heagerty, Anthony, Stefenelli, Thomas, Barrios, V., Lins, Robert, Barrios, Vivencio, Lins, R., Woittiez, Arend, Girerd, X., Böhm, Michael, Ewald, Silke, Girerd, Xavier   +20 more
core   +1 more source

Exposure the Hazardous Potential of Quinalphos: An In‐Depth Analysis for Environmental and Biological Effects on Human Health

IET Systems Biology, Volume 20, Issue 1, January/December 2026.
This study elucidates pesticide docking onto proteins encoded by differentially expressed genes, revealing interaction networks involving chemicals, genes, proteins, drugs and diseases. It highlights structural insights, regulatory pathways and potential therapeutic or environmental implications, providing a comprehensive understanding of the ...
Jyoti Kant Choudhari, Biju Prava Sahariah, Anand Kumar Jayapal, Jyotsna Choubey, Abhishek Tripathi   +4 more
wiley   +1 more source

Safety and Drug–Drug Interaction Burden of Direct‐Acting Antiviral Therapy for Hepatitis C: A Single‐Center Community Hospital Analysis

International Journal of Hepatology, Volume 2026, Issue 1, 2026.
Background Polypharmacy leads to drug–drug interactions (DDIs) with direct‐acting antivirals (DAAs). We quantified the DDI burden (Liverpool categories) and evaluated its association with effectiveness and safety. We assessed renal function as a predictor of adverse events (AEs) and reported loss to follow‐up (LTFU). Methods We retrospectively analyzed
Satoru Okabe, Akira Doi, Kengo Matsumoto, Masashi Yamamoto, Koji Fukui, Tsutomu Nishida, Sreeja Dattachoudhury   +6 more
wiley   +1 more source

Tablet Formulation Studies on Recrystallized Active Pharmaceutical Ingredients of Valsartan and Olmesartan Medoxomil [PDF]

, 2021
Both the Valsartan (VAL) and Olmesartan medoxomil (OLM) are widely prescribed anti-hypertensive agents with angiotensin II type I receptor antagonistic activity.
Rao, TP., Nalluri, Buchi N.
core   +1 more source

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil

Кардиоваскулярная терапия и профилактика, 2012
Cardiovascular (CV) disease is a major factor in mortality rates around the world and contributes to more than one-third of deaths in the US. The underlying cause of CV disease is atherosclerosis, a chronic inflammatory process that is clinically ...
R. P. Mason
doaj   +1 more source

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis

Clinical Pharmacology &Therapeutics, Volume 118, Issue 6, Page 1463-1476, December 2025.
Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu, Hui Shen, Jonathan Greenbaum, Qiao‐Rong Yi, Shuang Liang, Yue Zhang, Jia‐Chen Liu, Chuan Qiu, Lan‐Juan Zhao, Qing Tian, Kuan‐Jui Su, Zhe Luo, Li Wu, Xiang‐He Meng, Hong‐Mei Xiao, Yun Deng, Yang Li, Dragana Lovre, Vivian Fonseca, Fernando L. Sanchez, Li‐Jun Tan, Hong‐Wen Deng   +21 more
wiley   +1 more source

Pseudo‐Hypoaldosteronism Type 2 due to New Variants of KLHL3 Gene Diagnosed in an Adult Woman With Very High Sensitivity to Hydrochlorothiazide

Clinical Case Reports, Volume 13, Issue 9, September 2025.
ABSTRACT We report a case of pseudo‐hypoaldosteronism type 2 (PHA II) in a hypertensive 55‐year‐old woman who carried new variants of the KLHL3 gene. Hypersensitivity to hydrochlorothiazide was noted. Low dosages of hydrochlorothiazide were needed to restore potassium levels.
Massimo Giusti, Monica Repetto, Carmela Caputo   +2 more
wiley   +1 more source